| Title |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
|
|---|---|
| Published in |
BMC Medicine, March 2012
|
| DOI | 10.1186/1741-7015-10-28 |
| Pubmed ID | |
| Authors |
Gang Chen, Peter Kronenberger, Erik Teugels, Ijeoma Adaku Umelo, Jacques De Grève |
| Abstract |
The epidermal growth factor receptor (EGFR) is a validated therapeutic target in non-small cell lung cancer (NSCLC). However, current single agent receptor targeting does not achieve a maximal therapeutic effect, and some mutations confer resistance to current available agents. In the current study we have examined, in different NSCLC cell lines, the combined effect of RNA interference targeting the EGFR mRNA, and inactivation of EGFR signaling using different receptor tyrosine kinase inhibitors (TKIs) or a monoclonal antibody cetuximab. |
X Demographics
The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 2 | 33% |
| France | 1 | 17% |
| United States | 1 | 17% |
| Unknown | 2 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 67% |
| Scientists | 1 | 17% |
| Practitioners (doctors, other healthcare professionals) | 1 | 17% |
Mendeley readers
The data shown below were compiled from readership statistics for 124 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 2 | 2% |
| United States | 1 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 120 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 26 | 21% |
| Researcher | 19 | 15% |
| Student > Master | 18 | 15% |
| Student > Bachelor | 14 | 11% |
| Other | 8 | 6% |
| Other | 21 | 17% |
| Unknown | 18 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 32 | 26% |
| Agricultural and Biological Sciences | 29 | 23% |
| Biochemistry, Genetics and Molecular Biology | 19 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 6% |
| Chemistry | 6 | 5% |
| Other | 8 | 6% |
| Unknown | 22 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 17. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2018.
All research outputs
#1,846,320
of 22,663,969 outputs
Outputs from BMC Medicine
#1,251
of 3,397 outputs
Outputs of similar age
#11,336
of 160,638 outputs
Outputs of similar age from BMC Medicine
#9
of 35 outputs
Altmetric has tracked 22,663,969 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,397 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 43.6. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 160,638 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.